Dr. Martin Gleave is a Canadian surgeon and cancer researcher who was appointed to the Order of Canada in 2018.
Gleave is a co-founder and Executive Director of the Vancouver Prostate Centre as well as a head of a department at University of British Columbia.
Gleave's team was recognized in 2010 as the first in the world to develop an anti-clusterin agent.[1]
Awards
- Richard D. Williams MD Prostate Cancer Research Excellence Award[2]
- Eugene Fuller Triennial Prostate Award from the American Urological Association[2]
- Barringer Medal from the American Association of Genitourinary Surgeons[2]
- BC Biotech Innovation and Achievement Award[2]
- BC Innovation Council Frontiers in Research Award[2]
- 2013 Aubrey J. Tingle Prize from Michael Smith Foundation for Health Research[3]
References
- ^ Crawford, Tiffany (August 28, 2010). "New cancer drug will prolong lives, Vancouver scientists say". Vancouver Sun. Retrieved 9 January 2018.
- ^ a b c d e "DR. MARTIN GLEAVE APPOINTED TO THE ORDER OF CANADA". Vancouver Coastal Health Research Institute. Retrieved January 9, 2018.
- ^ "AJT Prize Recognizes Made-In-BC Advances In Prostate Cancer Treatment". msfhr.org. Retrieved January 9, 2018.